About IntegenX
IntegenX is a Healthcare company based in Pleasanton (United States) founded in 2006, and was acquired by Thermo Fisher Scientific in March 2018. Instruments for rapid human DNA identification are developed. IntegenX has raised $92.06 million across 9 funding rounds from investors including Thermo Fisher Scientific, Square 1 Bank and HHS. The company has 78 employees. IntegenX has completed 1 acquisition, including GenVault Corporation. The company was acqui-hired. IntegenX offers products and services including RapidHIT ID System and TaqMan Real-Time PCR Assays. Its focus areas include Life Sciences, Genomics, Applied Genomics and Other Applications. Its legal entity is Thermo Fisher Scientific Inc. Its competitors include DDC Paternity Tests, Othram and ANDE; 2 of its 3 listed competitors have raised funding.
Company details
Founded in 2006 and based in Pleasanton, United States, IntegenX operates in the forensics and law enforcement sector. Advanced fluidics, optics, and biochemistry are integrated into its proprietary platforms to create sample-to-answer products for DNA-based identity testing. As of January 2016, the RapidHIT ID and RapidHIT System, along with supporting reagent kits, are offered for these applications.
- Headquarters Pleasanton, United States
- Employees 78
- Stage Acquired
- SectorsHealthcare
- Website integenx.com
- Social LinkedIn X
- Acquired by Thermo Fisher Scientific (Mar 2018)
- Legal Name Thermo Fisher Scientific Inc.
- Annual Revenue$22.5 B (USD)14513as on Dec 31, 2024
- Net Profit$6.34 B (USD)6as on Dec 31, 2024
- EBITDA$1.96 B (USD)2as on Dec 31, 2024
- Total Equity Funding$92.06M (USD)
in 9 rounds
- Latest Funding Round$10M (USD), Debt – Venture
Sep 2014
- InvestorsThermo Fisher Scientific
& 12 more
- Employee Count78
- Investments & Acquisitions
- Acquired byThermo Fisher Scientific
(Mar 2018)
Products & Services of IntegenX
IntegenX offers a comprehensive portfolio of products and services, including RapidHIT ID System and TaqMan Real-Time PCR Assays.
Compact system for generating DNA profiles in forensic settings
Assays for DNA analysis in various scientific applications
Funding Insights of IntegenX
IntegenX has successfully raised a total of $92.06M across 9 strategic funding rounds. The most recent funding activity was a Debt β Venture round of $10 million completed in September 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $92.06M
- Total Rounds 9
- Last Round Debt – Venture β $10M
- First Round $4.5M
(Aug 2006)
- Investors Count 12
All 9 funding rounds of IntegenX with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2014 | $10M | Debt – Venture | β | β | |
| Dec 2012 | $48.84M | Series C | β | EW Healthcare Partners | |
| Dec 2011 | $5M | Debt – Conventional | β | β | |
| Jan 2011 | $20.62M | Series B | β | β | |
| Nov 2009 | $18.1M | Series B | β | β | |
| Sep 2009 | $843,715 | Grant | β | β | |
| May 2007 | $843,715 | Grant | β | β | |
| Sep 2006 | $843,715 | Grant | β | β | |
| Aug 2006 | $4.5M | Series A | β | β |
13 investors in total: 13 institutional.
Investors in IntegenX
IntegenX has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Thermo Fisher Scientific, Square 1 Bank and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Structured debt is provided to life sciences and technology firms. | 2004 | horizontechfinance.com | Farmington, United States | |
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
Expansion stage tech-focused VC firm investing primarily in the US | questm.com | Baltimore, United States | ||
Diversified investment management firm | 2000 | greenspringassociates.com | Owings Mills, United States | |
Early-stage US companies are invested in by RONA Holdings. | ronaholdings.com | Cupertino, United States | ||
Venture capital firm | iqt.org | Washington, Dc, United States | ||
Investments are directed toward semiconductors, telecommunications, software, and medical sectors. | samsungventures.com | Seoul, South Korea | ||
Growth-stage healthcare companies are invested in by EW Healthcare Partners. | ewhealthcare.com | New York, United States | ||
Sector-agnostic investments in late-stage startups are made by Cross Creek. | crosscreek.vc | Salt Lake City, United States | ||
Venture debt is provided globally across multiple sectors. | 1980 | westerntech.com | Portola Valley, United States |
Investor details for IntegenX
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by IntegenX
IntegenX has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include GenVault Corporation.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Biosamples are stabilized, transported, stored, and retrieved by GenVault. | genvault.com | Carlsbad, United States | 2000 | Jan 2011 | β’β’β’β’ |
Complete acquisition details for IntegenX
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of IntegenX
5 dated milestones of IntegenX across 12 years, from founding to its latest funding, stage changes and deals.
- Founded IntegenX is founded.
- Funding First funding round of $4.5M.
- Acquisition Acquires GenVault Corporation.
- Funding Latest funding round, Debt β Venture, of $10.0M.
- Exit Acquired by Thermo Fisher Scientific.
Competitors of IntegenX
IntegenX has 3 listed competitors in our database, 2 of them funded. They include DDC Paternity Tests, Othram and ANDE.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| dnacenter.com | 1995 | Fairfield, United States | DNA tests and personalized diagnostics are provided for various specialties. | |||
| othram.com | 2018 | Houston, United States | $33.16M | 22 | Genomic services are provided for forensic investigations and research. | |
| ande.com | 2000 | Waltham, United States | $131.3M | 49 | Rapid DNA systems are provided for forensic identification and diagnostics. |
Detailed competitors of IntegenX
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as IntegenX (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Integenx
Complete news archive for IntegenX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IntegenX
IntegenX was founded in 2006.
IntegenX is headquartered in Pleasanton, United States. It is registered at Pleasanton, California, United States.
IntegenX is a funded company, having raised a total of $92.06M across 9 funding rounds to date. The company's 1st funding round was a Series A of $4.5M, raised on Aug 2006.
IntegenX has 78 employees.
Annual revenue of IntegenX is $22.5B as on Dec 31, 2024.
Founded in 2006 and based in Pleasanton, United States, IntegenX operates in the forensics and law enforcement sector. Advanced fluidics, optics, and biochemistry are integrated into its proprietary platforms to create sample-to-answer products for DNA-based identity testing. As of January 2016, the RapidHIT ID and RapidHIT System, along with supporting reagent kits, are offered for these applications.
IntegenX's top competitors include DDC Paternity Tests, Othram and ANDE.
IntegenX offers RapidHIT ID System and TaqMan Real-Time PCR Assays.
IntegenX has made 1 acquisition, including GenVault Corporation.
IntegenX has 13 investors. Key investors include Thermo Fisher Scientific, Square 1 Bank, HHS, Horizon Tech Finance, and Western Technology Investment.
IntegenX operates through Thermo Fisher Scientific Inc..
Yes. IntegenX was acquired by Thermo Fisher Scientific in March 2018.

